Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Background Despite widespread use of multivitamin supplements, their effect on cognitive health-a critical issue with aging-remains inconclusive. To date, no long-term clinical trials have studied multivitamin use and cognitive decline in older persons. Objective To evaluate whether long-term multivitamin supplementation affects cognitive health in later life. Design Randomized, double-blind, placebo-controlled trial of a multivitamin from 1997 to 1 June 2011. The cognitive function substudy began in 1998. Up to 4 repeated cognitive assessments by telephone interview were completed over 12 years. (ClinicalTrials.gov: NCT00270647) SETTING: The Physicians' Health Study II. Patients 5947 male physicians aged 65 years or older. Intervention Daily multivitamin or placebo. Measurements A global composite score averaging 5 tests of global cognition, verbal memory, and category fluency. The secondary end point was a verbal memory score combining 4 tests of verbal memory, which is a strong predictor of Alzheimer disease. Results No difference was found in mean cognitive change over time between the multivitamin and placebo groups or in the mean level of cognition at any of the 4 assessments. Specifically, for the global composite score, the mean difference in cognitive change over follow-up was -0.01 SU (95% CI, -0.04 to 0.02 SU) when treatment was compared with placebo. Similarly, cognitive performance did not differ between the multivitamin and placebo groups on the secondary outcome, verbal memory (mean difference in cognitive change over follow-up, -0.005 SU [CI, -0.04 to 0.03 SU]). Limitation Doses of vitamins may be too low or the population may be too well-nourished to benefit from a multivitamin. Conclusion In male physicians aged 65 years or older, long-term use of a daily multivitamin did not provide cognitive benefits. Primary funding source National Institutes of Health, BASF, Pfizer, and DSM Nutritional Products.

Key findings

Why it matters

In this randomized trial of 5,947 male physicians aged 65 or older followed for up to 12 years, long-term multivitamin supplementation showed no difference from placebo in mean cognitive change over time or in mean cognition at any of the four assessments. The result was null for both the global composite score and the verbal memory score.

Study details

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 2 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 69 of 100.69 of 100 points earned31 not earned

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of internal medicine)
Journal's citation record 4 / 4 Annals of Internal Medicine: journal h-index 648 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded 2 / 2 Randomised and blinded or placebo-controlled (as stated in the record)
Times cited 5 / 7 Cited 109 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.3 citations a year over 15 year(s) since 2013
Impact for its field and year 4 / 6 Cited 10.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Howard D. Sesso: h-index 103 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24490265)
Free to read 0 / 2 Behind a paywall — scores zero
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Grodstein, F., O'Brien, J., Kang, J. H., Dushkes, R., Cook, N. R., Okereke, O., et al. (2013). Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Annals of internal medicine. https://doi.org/10.7326/0003-4819-159-12-201312170-00006

Vancouver

Grodstein F, O'Brien J, Kang JH, Dushkes R, Cook NR, Okereke O, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Annals of internal medicine. 2013. doi:10.7326/0003-4819-159-12-201312170-00006. PMID: 24490265.

BibTeX

@article{grodstein2013-24490265,
  author  = {Grodstein, F. and O'Brien, J. and Kang, J. H. and Dushkes, R. and Cook, N. R. and Okereke, O. and Manson, J. E. and Glynn, R. J. and others},
  title   = {{Long-term multivitamin supplementation and cognitive function in men: a randomized trial}},
  journal = {Annals of internal medicine},
  year    = {2013},
  doi     = {10.7326/0003-4819-159-12-201312170-00006},
  pmid    = {24490265},
  url     = {https://doi.org/10.7326/0003-4819-159-12-201312170-00006}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments

Similar studies

More on Treatments

See all studies in Treatments →